Foventa Therapeutics is advancing FOV407, a topical SRPK1 inhibitor designed to address vascular leakage in non-proliferative diabetic retinopathy through eye drop administration. Early Phase Ib/IIa data suggest the molecule suppresses harmful leakage, with Phase IIb trials in preparation following FDA guidance.
Key Points
- FOV407 targets VEGF pathway via SRPK1 inhibition in retinal tissue
- Early data show suppression of vascular leakage in NPDR patients
- Non-invasive eye drop formulation; Phase IIb trial design FDA-validated
Longevity Analysis
Diabetic retinopathy represents a convergence of metabolic dysfunction, vascular integrity failure, and tissue regeneration collapse. A topical therapeutic that halts vascular leakage without systemic administration addresses a mechanism central to diabetic microvascular disease—the same pathological process that drives nephropathy and neuropathy. Success here could inform broader strategies for protecting vascular endothelial function in metabolic disease, and the non-invasive delivery mechanism removes barriers to compliance and systemic exposure.
Original published by Longevity.Technology.